Preclinical development of T cell receptor gene therapy

Current Opinion in Immunology

Volumn 21, Issue 2, 2009, Pages 209-214

  Bendle, Gavin M ^a   Haanen, John BAG ^a   Schumacher, Ton NM ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; AUTOIMMUNITY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA MODIFICATION; GENETIC ENGINEERING; HUMAN; IMMUNOLOGICAL TOLERANCE; MELANOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; REVIEW; T LYMPHOCYTE RECEPTOR GENE; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 65249096622     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.02.007     Document Type: Review

References (51)

1. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
2. Theobald M., Biggs J., Hernandez J., Lustgarten J., Labadie C., and Sherman L.A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185 (1997) 833-841
3. Romieu R., Baratin M., Kayibanda M., Lacabanne V., Ziol M., Guillet J.G., and Viguier M. Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J Immunol 161 (1998) 5133-5137
4. Schumacher T.N. T-cell-receptor gene therapy. Nat Rev Immunol 2 (2002) 512-519
5. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., and Schumacher T.N. Immunotherapy through TCR gene transfer. Nat Immunol 2 (2001) 957-961
6. Tahara H., Fujio K., Araki Y., Setoguchi K., Misaki Y., Kitamura T., and Yamamoto K. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J Immunol 171 (2003) 2154-2160
7. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., Sato T., Abe H., Fujio K., Yamamoto K., Kitamura T., et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 64 (2004) 386-390
8. Morris E.C., Tsallios A., Bendle G.M., Xue S., and Stauss H.J. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumour protection. Proc Natl Acad Sci U S A 102 (2005) 7934-7939
9. de Witte M.A., Coccoris M., Wolkers M.C., van den Boom M.D., Mesman E.M., Song J.Y., van der Valk M., Haanen J.B., and Schumacher T.N. Targeting self-antigens through allogeneic TCR gene transfer. Blood 108 (2006) 870-877. A murine study that demonstrated for the first time that TCR gene transfer could be used to break tolerance to a defined self-antigen.
10. de Witte M.A., Bendle G.M., van den Boom M.D., Coccoris M., Schell T.D., Tevethia S.S., van Tinteren H., Mesman E.M., Song J.Y., and Schumacher T.N. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol 181 (2008) 2563-2571. A paper showing that TCR gene transfer can be utilized to break tolerance to a tumor-associated self-antigen and inhibit tumor progression in a murine model of spontaneous prostate carcinoma.
11. Abad J.D., Wrzensinski C., Overwijk W., De Witte M.A., Jorritsma A., Hsu C., Gattinoni L., Cohen C.J., Paulos C.M., Palmer D.C., et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother 31 (2008) 1-6
12. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129. The first and, at present, the only clinical trial of TCR gene transfer. This study in metastatic melanoma patients demonstrated that the clinical implementation of TCR gene transfer is feasible.
13. Jorritsma A., Gomez-Eerland R., Dokter M., van de Kasteele W., Zoet Y.M., Doxiadis I.I., Rufer N., Romero P., Morgan R.A., Schumacher T.N., et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110 (2007) 3564-3572
14. Sadovnikova E., and Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci U S A 93 (1996) 13114-13118
15. Heemskerk M.H., Hoogeboom M., de Paus R.A., Kester M.G., van der Hoorn M.A., Goulmy E., Willemze R., and Falkenburg J.H. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102 (2003) 3530-3540
16. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2 (2001) 962-970
17. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., and Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A 97 (2000) 5387-5392
18. Varela-Rohena A., Molloy P.E., Dunn S.M., Li Y., Suhoski M.M., Carroll R.G., Milicic A., Mahon T., Sutton D.H., Laugel B., et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14 (2008) 1390-1395. Study that demonstrates the superior function of T cells transduced with TCRs of supraphysiological affinity against HIV escape variants in in vitro systems.
19. de Witte M.A., Jorritsma A., Kaiser A., van den Boom M.D., Dokter M., Bendle G.M., Haanen J.B., and Schumacher T.N. Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 181 (2008) 5128-5136. This study identifies three parameters that influence the in vivo function and persistence of TCR-modified T cells.
20. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
21. Rosenberg S.A., and Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101 Suppl 2 (2004) 14639-14645
22. Jones L.A., Chin L.T., Longo D.L., and Kruisbeek A.M. Peripheral clonal elimination of functional T cells. Science 250 (1990) 1726-1729
23. Rocha B., and von Boehmer H. Peripheral selection of the T cell repertoire. Science 251 (1991) 1225-1228
24. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., and Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 (2008) 271-275
25. Bendle G.M., Holler A., Pang L.K., Hsu S., Krampera M., Simpson E., and Stauss H.J. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res 64 (2004) 8052-8056
26. Rocha B., Tanchot C., and Von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 177 (1993) 1517-1521
27. Ramsdell F., and Fowlkes B.J. Maintenance of in vivo tolerance by persistence of antigen. Science 257 (1992) 1130-1134
28. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
29. Hua C., Boyer C., Buferne M., and Schmitt-Verhulst A.M. Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect several clone-specific molecules. J Immunol 136 (1986) 1937-1944
30. Quinn E.R., Lum L.G., and Trevor K.T. T cell activation modulates retrovirus-mediated gene expression. Hum Gene Ther 9 (1998) 1457-1467
31. Coccoris M., Swart E., de Witte M.A., van Heijst J.W., Haanen J.B., Schepers K., and Schumacher T.N. Long-term functionality of TCR-transduced T cells in vivo. J Immunol 180 (2008) 6536-6543
32. Rubinstein M.P., Salem M.L., Kadima A.N., Nguyen C.L., Gillanders W.E., Nishimura M.I., and Cole D.J. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther 16 (2009) 171-183
33. Bakker A.H., and Schumacher T.N. MHC multimer technology: current status and future prospects. Curr Opin Immunol 17 (2005) 428-433
34. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., et al. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
35. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008) 3132-3142
36. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003) 255-256
37. Newrzela S., Cornils K., Li Z., Baum C., Brugman M.H., Hartmann M., Meyer J., Hartmann S., Hansmann M.L., Fehse B., et al. Resistance of mature T cells to oncogene transformation. Blood 112 (2008) 2278-2286. This study shows that the genotoxic risk of retroviral gene transfer is substantially lower for mature T cells as compared with hematopoietic progenitor cells.
38. Weinhold M., Sommermeyer D., Uckert W., and Blankenstein T. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol 179 (2007) 5534-5542. This study provides evidence that the activation of endogenous self-reactive T cells is unlikely to result in major autoimmune pathology upon TCR gene transfer.
39. Kuball J., Dossett M.L., Wolfl M., Ho W.Y., Voss R.H., Fowler C., and Greenberg P.D. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109 (2007) 2331-2338. Study describing the use of an engineered disulfide to limit the formation of auto-aggressive mixed TCR dimers, of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
40. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., and Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 67 (2007) 3898-3903. Study describing the use of an engineered disulfide to limit the formation of auto-aggressive mixed TCR dimers, of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
41. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., and Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66 (2006) 8878-8886. Study describing the use of murine constant domains to limit the formation of auto-aggressive mixed TCR dimers, of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
42. Voss R.H., Willemsen R.A., Kuball J., Grabowski M., Engel R., Intan R.S., Guillaume P., Romero P., Huber C., and Theobald M. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol 180 (2008) 391-401. Study describing a TCR engineering strategy that may be utilized to limit the formation of auto-aggressive mixed TCR dimers, of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
43. Sebestyen Z., Schooten E., Sals T., Zaldivar I., San Jose E., Alarcon B., Bobisse S., Rosato A., Szollosi J., Gratama J.W., et al. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol 180 (2008) 7736-7746. Study describing the use of TCR fusion receptors to limit the formation of auto-aggressive mixed TCR dimers, of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
44. Heemskerk M.H., Hoogeboom M., Hagedoorn R., Kester M.G., Willemze R., and Falkenburg J.H. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 199 (2004) 885-894
45. Willemsen R.A., Weijtens M.E., Ronteltap C., Eshhar Z., Gratama J.W., Chames P., and Bolhuis R.L. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 7 (2000) 1369-1377
46. Zhang T., He X., Tsang T.C., and Harris D.T. Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther 11 (2004) 487-496
47. van der Veken L.T., Hagedoorn R.S., van Loenen M.M., Willemze R., Falkenburg J.H., and Heemskerk M.H. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res 66 (2006) 3331-3337. Study describing the use of gamma-delta T cells as recipient T cells to limit the formation of auto-aggressive mixed TCR dimers. Together with earlier work from this group based on the use of polyclonal T cell populations, this work is of particular relevance in view of increasing concerns regarding mixed TCR dimer-mediated toxicity.
48. van der Veken L.T., Coccoris M., Swart E., Falkenburg J.H.F., Schumacher T.N., and Heemskerk M.H.M. αβ T cell receptor transfer to γδ T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol 182 (2009) 164-170
49. Kieback E., Charo J., Sommermeyer D., Blankenstein T., and Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci U S A 105 (2008) 623-628
50. de Witte M.A., Jorritsma A., Swart E., Straathof K.C., de Punder K., Haanen J.B., Rooney C.M., and Schumacher T.N. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 180 (2008) 6365-6373
51. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 21 (2009) 190-199